ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA

BACKGROUND: EGFR is a key oncogenic target for the treatment of glioblastoma. EGFR amplification is detected in ~50% of tumors. Depatuxizumab mafodotin (depatux-m), formerly called ABT-414, is a tumor-specific antibody-drug conjugate that preferentially targets tumors with EGFR amplification. Herein...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: van den Bent, Martin, Roberts-Rapp, Lisa A, Ansell, Peter J, Lee, James, Looman, Jim, Bain, Earle, Ocampo, Christopher, Holen, Kyle D, Gomez, Erica J, Lassman, Andrew B
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693085/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.010
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg